A study of the thermal stability of Brucellosis IRIBA strain vaccine after reconstitute

Document Type : Full Research Paper

Authors

1 Dept. of Bacterial vaccines Quality Control. Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organisation (AREEO), Karaj, Iran.

2 Bagheri Nejad, R., Dept. of Brucella Vaccine Production. Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organisation (AREEO), Karaj, Iran.

Abstract

Brucellosis is one of the most important zoonotic diseases, in most countries, including Mediterranean and Middle Eastern countries in the region, including Iran prevalent, animals vaccination is the best way to prevent Brucellosis. The purpose of this study was to evaluate the quality IRIBA vaccines after reconstitution of lyophilized vials vaccine. In this experimental study after reconstitution Six vials of Brucellosis IRIBA strain vaccine, In different temperature conditions 4°C, 25°C and 37°C were put, and at zero time, one hour, four hours and 12 hours, accordance with OIE 2016 requirment live bacteria in vaccine (viable count test) was examined, Fisher was used For measuring the moisture content of the device Caral, The results of this study showed average moisture content for 3 vials of vaccine selected as a statistical sample is equal to 2/49 percent, and also the loss of live IRIBA vaccines for the suspension is placed at 4 ° C at one, four and 12 hours after the respectively is equal to 12.37%,14.29%,18.13%, and suspension is placed at 25 ° C, 15.83%, 20.06%, 25.05%, and suspension is placed at 37 ° C, 22.9%, 26,97% ,55.41%. According to these results, IRIBA Brucellosis vaccines can be stabled at least 12 hours after reconstitution at 4°C, 25°C and 37°C and conforming to the requirements of OIE 2016 (10-34 × 109 cfu/dose).

Keywords

Main Subjects

References

1. Asghari Ghadi, Mehdi. 2011.Study the effectiveness of the vaccine FdRev.1 in sheep Semnan province in 2011. 4 th National Iranian congress of Brucellosis, Trhran. Iran. 13-15 December 2011. pp 8-9.
2. Aldomy, F., Alkhawaldeh, M. and Younis, I.B., 2009. Immune responses of goats (Shami breed) to vaccination with a full, reduced and conjunctival dose of brucevac (Brucella melitensis Rev. 1) vaccine. Pak. Vet. J, 29, pp.149-153.
3. Cutler, S.J., Whatmore, A.M. and Commander, N.J., 2005. Brucellosis–new aspects of an old disease. Journal of applied microbiology, 98(6), pp.1270-1281.
4. Dostdari, S. Hassannia, E. khafri, A. Anahita, E. Alamiyan,S. Bagherinejad, R. Baggeri, S. 2015. Stability Study of Rev.1 Reduc dose Brucellosis Vaccine Produced by Razi Institute in Iran. 19th Iranian Veterinary Congress. Tehran. Iran. 25-27 April 2015. PP 1.
5. Hasannia, E., Soleimani, S., Alamian, S., Behrozikhah, A., Emadi, A. and Dostdari, S., 2015. Stability study of IRIBA brucellosis full-dose and reduced-dose vaccine produced by Razi Institute in Iran. Archives of Razi Institute, 70(1), pp.37-44
6. Jones, L.M., Entessar, F. and Ardalan, A.1964.. Comparison of living vaccine in producing immunity against natural Brucella melitensis infection in sheeps and goats in Iran. Computational and Mathematical Organization Theory Vol.74 ,No 1.
7. Hirsh, D.C. and Zee, Y.C., 1999. Veterinary Microbiology. USA, Black well science. Pp. 115-249
8. Khorasgani, R., M. Esmaeili, M.R. Pourkarim, A.R. Mankhian and T.Z. Salehi, 2008. Antibrucella antibodies in blood donors in Boushehr. Iran Comparative Clinical Pathol., 17: 267-269
9. Lapaque, N., Moriyon, I., Moreno, E. and Gorvel, J.P., 2005. Brucella lipopolysaccharide acts as a virulence factor. Current opinion in microbiology, 8(1), pp.60-66.
10. Simmons, M.M., Stack, M.J., Konold, T. and Webster, K., 2009. OIE manual of diagnostic tests and vaccines for terrestrial animals.
11. Radostits, O.M., Gay, C.C., Hinchcliff, K.W. and Constable, P.D., 2007. Diseases associated with helminth parasites. Veterinary Medicine: A textbook of the diseases of cattle, horses, sheep, pigs, and goats. 10th ed. Saunders Elsevier, Philadelphia, pp.1541-1563.
12. Ragan VE. 2002. The animal and plant health inspection service (APHIS) brucellosis eradication program in the United States. Vet Microbiol.; 90(1-4): 11-8.
13. Shayestehpour, M., Shafyi, A., Taqavian, M., Esna-ashari, F., Mohammadi, A. and Shahbazi, R., 2012. A study of the thermal stability of measles vaccine produced by AIK-C strain. Arak Medical University Journal, 15(4), pp.26-33.
14. Soleimani, S., 2016. Stability Study of Measles AIK-C Strain, Mumps RS-12 Strain and Rubella Takahashi Strain in MMR Vaccine. Archives of Razi Institute, 71(1), pp.21-28.
15. Geneva, J.F.W., 1986. Expert committee on brucellosis (sixth report). Geneva: World Health Organization.
16. Joint, F.A.O., 1970. WHO Expert Committee on Brucellosis (1971). Fifth report, pp.71-72.
17. Cosivi, O. and Corbel, M.J., 1998. WHO consultation on the development of new/improved brucellosis vaccines. Biologicals, 26(4), pp.361-363.
18. World Health Organization, 1977. Requirements for Brucella melitensis strain Rev 1 vaccine (live for veterinary use). WHO Tech. Rep. Ser, 610, pp.85-97.
19. World Health Organization, 1997. Fact sheet N173. World Health Organization, Geneva, Switzerland.
20. Zowghi, E. and Ebadi, A., 1985. Serological investigations on brucellosis in cattle, sheep and goats in Iran. Revue Scientifique et Technique de l'OIE (France).
21. OIE Manual of diagnostic tests and vaccines for terrestrial animals (2016), 7th edn, world organization for animal health. Chapter 2.4.3.
22. The Offical compendia of standard, U.S. Pharmacopoeia, the standard of quality (2012). USB 35, NF30- Water Determination(921).
Veterinary Research & Biological Products
Volume 30, Issue 4
December 2017
Pages 85-91

Files

History

  • Receive Date: 06 March 2017
  • Revise Date: 27 May 2017
  • Accept Date: 27 May 2017

Share

How to cite

Statistics